









Markets
/
Stocks
/
nasdaq-ycbd
/

cbdMD Inc

YCBD

0.923USD

-0.021-2.21%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

8.23MMarket Cap

LossP/E TTM



cbdMD Inc

0.923

-0.021-2.21%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of cbdMD Inc

Currency: USD Updated: 2026-02-06

Key Insights

cbdMD Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 103 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.00.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

cbdMD Inc's Score

Industry at a Glance

Industry Ranking

103 / 159

Overall Ranking

282 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

cbdMD Inc Highlights

StrengthsRisks

cbdMD, Inc. is a cannabidiol (CBD) company. The Company has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The Company's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.

Growing

The company is in a growing phase, with the latest annual income totaling USD 19.19M.

Fairly Valued

The company’s latest PE is -0.85, at a medium 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 98.21K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.27.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

2.000

Target Price

+111.91%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of cbdMD Inc is 7.84, ranking 95 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 4.72M, representing a year-over-year increase of 3.61%, while its net profit experienced a year-over-year increase of 41.14%.

Score

Industry at a Glance

Previous score

7.84

Change



Financials

7.48

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.01

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.48

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.24

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

cbdMD Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of cbdMD Inc is 6.92, ranking 107 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -0.85, which is -96.68% below the recent high of -0.03 and -332.79% above the recent low of -3.67.

Score

Industry at a Glance

Previous score

6.92

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 103/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of cbdMD Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 2.00, with a high of 2.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

2.000

Target Price

+111.91%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

cbdMD Inc

YCBD

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of cbdMD Inc is 5.44, ranking 140 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.25 and the support level at 0.66, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.49

Change

-0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.027

Neutral

RSI(14)

47.834

Neutral

STOCH(KDJ)(9,3,3)

35.268

Neutral

ATR(14)

0.126

High Vlolatility

CCI(14)

56.779

Neutral

Williams %R

65.910

Sell

TRIX(12,20)

-1.212

Sell

StochRSI(14)

68.674

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

0.924

Sell

MA10

0.876

Buy

MA20

0.917

Buy

MA50

1.022

Sell

MA100

0.970

Sell

MA200

0.961

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of cbdMD Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 5.38%, representing a quarter-over-quarter increase of 23.56%. The largest institutional shareholder is The Vanguard, holding a total of 98.21K shares, representing 0.94% of shares outstanding, with 349.42% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Porter (Jeffrey H)

73.26K

Crc Investment Fund LP

436.15K

-64.64%

CSS, LLC

142.62K

The Vanguard Group, Inc.

Star Investors

51.56K

Chapin Davis Asset Management

121.55K

+2.47%

Kennedy (Thomas Ronan)

454.31K

+4778.27%

Alesco Advisors LLC

68.51K

Roe (Kevin Charles)

4.52K

Commonwealth Financial Network

16.25K

Scientech Research LLC

15.41K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of cbdMD Inc is 1.13, ranking 155 out of 159 in the Pharmaceuticals industry. The company's beta value is 2.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. cbdMD Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.